Who are Dendreon NASDAQ: DNDN www.dendreon.com's investors?

Dendreon NASDAQ: DNDN www.dendreon.com's investors include Rho Capital Partners, Rho Ventures, Sanderling Ventures.

Dendreon NASDAQ: DNDN www.dendreon.com

Founded 1992 · 584 employees on LinkedIn · 3 known investors

Dendreon develops and manufactures cellular immunotherapies, including PROVENGE (sipuleucel-T), an FDA-approved cellular immunotherapy for prostate cancer patients. The company also provides cell therapy research, development, and contract manufacturing services to other companies bringing cellular therapies to market.

Biotech Healthtech

Founders & leadership

William Amickin

Investors · 3

Rho Capital PartnersNew York

Rho VenturesNew York · $2M – $15M

Sanderling VenturesSan Mateo · $50K – $1M

Competitors · 2

by search overlap

Regeneron NASDAQ: REGN www.regeneron.com31 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.

Aldevron21 shared keywordsAldevron manufactures plasmid DNA, mRNA, proteins, and gene editing components at research, GMP-Source, and cGMP grades for pharmaceutical and biotechnology customers developing therapies and vaccines. It provides catalog products and custom manufacturing services, including LNP encapsulation and sterile fill-finish, supporting clinical trial and drug product development.

Companies competing with Dendreon NASDAQ: DNDN www.dendreon.com for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Dendreon NASDAQ: DNDN www.dendreon.com do?: Dendreon develops and manufactures cellular immunotherapies, including PROVENGE (sipuleucel-T), an FDA-approved cellular immunotherapy for prostate cancer patients. The company also provides cell therapy research, development, and contract manufacturing services to other companies bringing cellular therapies to market.
Who are Dendreon NASDAQ: DNDN www.dendreon.com's investors?: Dendreon NASDAQ: DNDN www.dendreon.com's investors include Rho Capital Partners, Rho Ventures, Sanderling Ventures.